The Department of Maxillofacial and Otorhinolaryngology Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, 300060, China.
The Department of Maxillofacial and Otorhinolaryngology Oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, 300060, China.
Eur J Surg Oncol. 2021 Jul;47(7):1727-1733. doi: 10.1016/j.ejso.2021.02.010. Epub 2021 Feb 18.
Delphian lymph node metastasis (DLNM) has proven to be a risk factor for a poor prognosis in head and neck malignancies. This study aimed to reveal the clinical features and evaluate the predictive value of the Delphian lymph node (DLN) in papillary thyroid carcinoma (PTC) to guide the extent of surgery.
Tianjin Medical University Cancer Institute and Hospital pathology database was reviewed from 2017 to 2020, and 516 PTC patients with DLN detection were enrolled. Retrospective analysis was performed, while multivariate analysis was performed to identify the risk factors for DLNM.
Among the 516 PTC patients with DLN detection, the DLN metastasis rate was 25.39% (131/516). Tumor size >1 cm, location in the upper 1/3, central lymph node metastasis (CLNM), lateral lymph node metastasis (LLNM) and lymphovascular invasion were independent risk factors for DLNM. Patients with DLNM had a higher incidence of ipsilateral CLNM, contralateral CLNM (CCLNM) and LLNM, and larger numbers and size of metastatic CLNs than those without DLNM. The incidence of CLNM among cN0 patients with DLNM was higher than that among those without DLNM. The incidence of CCLNM among unilateral cN + patients with DLNM was similarly higher than that among patients without DLNM.
DLNM indicates a high likelihood and large number of cervical lymph nodes metastases in PTC patients. Surgeons are strongly recommended to detect DLN status during operation by means of frozen pathology, so as to evaluate the possibility of cervical nodal metastasis and decide the appropriate extent of surgery.
Delphian 淋巴结转移(DLNM)已被证明是头颈部恶性肿瘤预后不良的危险因素。本研究旨在揭示 Delphian 淋巴结(DLN)在甲状腺乳头状癌(PTC)中的临床特征,并评估其对预测颈部淋巴结转移的价值,以指导手术范围。
回顾性分析 2017 年至 2020 年天津医科大学肿瘤医院病理数据库中 516 例有 DLN 检测的 PTC 患者的临床病理资料,采用多因素分析识别 DLNM 的危险因素。
在 516 例有 DLN 检测的 PTC 患者中,DLN 转移率为 25.39%(131/516)。肿瘤直径>1cm、位置在上 1/3 区、中央区淋巴结转移(CLNM)、侧颈部淋巴结转移(LLNM)和脉管侵犯是 DLNM 的独立危险因素。DLNM 患者同侧 CLNM、对侧 CLNM(CCLNM)和 LLNM 的发生率更高,转移的 CLN 数量和大小也更大。有 DLNM 的 cN0 患者 CLNM 的发生率高于无 DLNM 的患者。有 DLNM 的单侧 cN+患者 CCLNM 的发生率也高于无 DLNM 的患者。
DLNM 提示 PTC 患者颈部淋巴结转移的可能性高、转移数量多。强烈建议外科医生在手术中通过冷冻病理检测 DLN 状态,以评估颈部淋巴结转移的可能性,并决定适当的手术范围。